Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19.

Xiao-Jian ZhouArantxa HorgaAdeep PuriLee WinchesterMaureen MontrondKeith PietropaoloBruce BelangerCourtney V FletcherJanet Hammond

Published in: The Journal of antimicrobial chemotherapy (2024)

The favourable pharmacokinetics and safety profile of bemnifosbuvir demonstrates its potential as an oral antiviral treatment for COVID-19, with 550 mg bemnifosbuvir twice daily currently under further clinical evaluation in persons with COVID-19.

Keyphrases

coronavirus disease
sars cov
clinical evaluation
endothelial cells
respiratory syndrome coronavirus
physical activity
cancer therapy
induced pluripotent stem cells
replacement therapy
pluripotent stem cells